MINNEAPOLIS, April 26,
2024 /PRNewswire/ -- Bio-Techne Corporation
(NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are
pleased to announce the development of Bio-Marker Pathfinder (BMP),
a first of its kind ocular biomarker kit, as a point-of-care
application. Novomol-Dx is a molecular diagnostics company focused
on commercializing tests for the diagnosis and treatment of
ophthalmic diseases utilizing biomarkers discovered over the last
decade at Narayana Nethralaya Foundation, in association with Grow
Laboratories & Narayana Nethralaya, a specialty eye care
hospital chain in Bangalore
India.
The BMP kit runs on Bio-Techne's Ella™, a benchtop automated
immunoassay platform leveraging Bio-Techne's R&D Systems
branded reagents to deliver accurate, reliable, and highly
reproducible data in less than 90 minutes. Ella's
microfluidic-based cartridges with separate channels enable
precision multiplexing in a hands-free system, making it ideal for
diagnostic clinical use. Novomol-Dx relied on a proprietary
algorithm to develop the normative data, disease-associated data,
and AI-based predictive algorithms for ocular surface and retinal
conditions. The complete solution is branded as BioM-Pathfinder.
The novel applications for the BMP kit are in Dry Eye Disease,
Diabetic Retinopathy and patient stratification or monitoring
associated with ocular surgeries and treatments.
"The BMP kit's ability to produce clinically
actionable data using tear samples is a game-changer for the
diagnosis of these conditions. This kit fills a significant unmet
need, with an estimated 15 million suffering from various
ophthalmic diseases in India.
Beyond ocular applications, we believe the underlying technology is
potentially relevant for disease-associated diagnostic or
prognostic applications in the future," stated Dr. Rohit Shetty, Chairman at Narayana
Nethralaya.
"There is a great need for improved ocular diagnostic tools, and
the BMP kit will save time by enabling an accurate diagnostic
solution to the millions impacted by ophthalmic diseases," said Dr.
Naren Shetty, Vice-Chairman of
Narayana Nethralaya.
"The BMP multi-analyte kit holds great promise for the potential
use of Ella in proteomic diagnostic applications," commented
Will Geist, President of
Bio-Techne's Protein Sciences Segment. "We are happy to partner
with this leading ocular biomarker research group and eye care
institute to deliver a much-needed diagnostic tool for patients
impacted by these diseases."
"We are excited to be able to translate the years of biomarker
research in eye diseases to an application that can benefit
clinicians and patients," said Dr. Arkasubhra Ghosh, Director
of GROW research labs at Narayana Nethralaya Foundation. "The
multiple biomarker diagnostic design establishes a platform for
future expansion to broader disease applications across ophthalmic
conditions, potentially including a non-invasive tear-based
diagnosis for systemic conditions."
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated over $1.1
billion in net sales in fiscal 2023 and has approximately
3,100 employees worldwide. For more information on Bio-Techne and
its brands, please visit http://www.bio-techne.com or follow the
Company on social media at Facebook, LinkedIn, Twitter or
YouTube.
About Novomol-Dx
Novomol-Dx is a start-up
collaborative initiative of Narayana Nethralaya Foundation to bring
out the solutions researched at their Grow Laboratories to the
local India and international
markets. Narayana Nethralaya group of hospitals are one of the best
hospitals in India known for their
quality care. Novomol-Dx is formed by a team of expert
professionals with huge years of experience in the related field
and have been associated with setting up successful multinational
ventures. For more details about Novomol-DX, please visit
http://www.novomoldx.com.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-and-novomol-dx-announce-point-of-care-ocular-biomarker-assay-302128379.html
SOURCE Bio-Techne Corporation